Live
Insilico MedicineInsilico Medicine Showcases AI-Driven Inhaled Therapy for Pulmonary Fibrosis at ATS Summit - TipRanksSamsung BiologicsCDMOs turn to pharma facility acquisitions amid manufacturing realignment: GlobalData - megaproject.comThermo FisherIs It Time To Reconsider Thermo Fisher Scientific (TMO) After Its Recent Share Price Slide? - simplywall.stAmgenAmgen Inc stock (US0311621009): lungs cancer setback meets steady biotech cash flow - AD HOC NEWSIlluminaIllumina Inc stock (US4523271090): gene sequencing player in focus after latest earnings and divesti - AD HOC NEWSMerck & Co.Merck & Co., Inc. stock (US58933Y1055): Keytruda momentum and fresh earnings keep big pharma in focu - AD HOC NEWSCharles RiverCharles River Labs stock (US14149Y1082): 4.45% slide puts support zone back in focus - AD HOC NEWS10x Genomics NewsThe Bull Case For 10x Genomics (TXG) Could Change Following Mixed Q1 Results And Reaffirmed Guidance - simplywall.stQiagenQiagen N.V. stock (NL0012169213): Q1 2026 earnings and outlook keep diagnostics specialist in focus - AD HOC NEWSIntuitive SurgicalIntuitive Surgical stock (US46120E6023): earnings momentum and robotic surgery demand in focus - AD HOC NEWSCellThe temporal architecture of the seminiferous epithelial cycle revealed by spatial transcriptomicsCellCell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis
Lonza News Apr 1, 2026

Lonza Group (SWX:LONN) Is Up 5.8% After 25% Dividend Hike And Board Refresh - Has The Bull Case Changed? - simplywall.st

Lonza Group (SWX:LONN) Is Up 5.8% After 25% Dividend Hike And Board Refresh - Has The Bull Case Changed? - simplywall.st

Original
Body unavailable. Use the original source.